Linked Life Data

6546301

Source:http://linkedlifedata.com/resource/pubmed/id/6546301

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6546301rdf:typepubmed:Citationlld:pubmed
pubmed-article:6546301lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:6546301lifeskim:mentionsumls-concept:C0205653lld:lifeskim
pubmed-article:6546301lifeskim:mentionsumls-concept:C0684224lld:lifeskim
pubmed-article:6546301lifeskim:mentionsumls-concept:C0346979lld:lifeskim
pubmed-article:6546301lifeskim:mentionsumls-concept:C0035412lld:lifeskim
pubmed-article:6546301lifeskim:mentionsumls-concept:C0011900lld:lifeskim
pubmed-article:6546301lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:6546301pubmed:issue2lld:pubmed
pubmed-article:6546301pubmed:dateCreated1984-2-20lld:pubmed
pubmed-article:6546301pubmed:abstractTextThirty children and adolescents with rhabdomyosarcoma (RMS) entered on IRS-1 in a 5-year period had bone marrow metastases (BMM) at diagnosis. BMM at diagnosis occurred in 30/103 patients (29%) with Clinical Group IV RMS. On the average, patients with BMM were older with more extremity primaries than other IRS-1 patients. Alveolar histology was present in 15/30 patients (50%) with BMM, compared to 19% on IRS-1. Eleven patients received vincristine, dactinomycin, cyclophosphamide (VAC), while 19 patients received VAC with Adriamycin (ADR). The overall complete response (CR) rate was 60%. The median disease-free survival times by treatment were 17 weeks with VAC and 32 weeks for VAC + ADR (P greater than 0.10). Relapse from CR in Clinical Group IV patients with BMM occurred in 16/18 patients (89%) and was significantly higher than in 17/29 Clinical Group IV patients (59%) without BMM (P less than 0.035). BMM at diagnosis in children and adolescents with RMS is frequently associated with alveolar histology and is a poor prognostic sign.lld:pubmed
pubmed-article:6546301pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6546301pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6546301pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6546301pubmed:languageenglld:pubmed
pubmed-article:6546301pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6546301pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6546301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6546301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6546301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6546301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6546301pubmed:statusMEDLINElld:pubmed
pubmed-article:6546301pubmed:monthJanlld:pubmed
pubmed-article:6546301pubmed:issn0008-543Xlld:pubmed
pubmed-article:6546301pubmed:authorpubmed-author:RagabA HAHlld:pubmed
pubmed-article:6546301pubmed:authorpubmed-author:RuymannF BFBlld:pubmed
pubmed-article:6546301pubmed:authorpubmed-author:DonaldsonM...lld:pubmed
pubmed-article:6546301pubmed:authorpubmed-author:NewtonW AWAJrlld:pubmed
pubmed-article:6546301pubmed:authorpubmed-author:FoulkesMMlld:pubmed
pubmed-article:6546301pubmed:issnTypePrintlld:pubmed
pubmed-article:6546301pubmed:day15lld:pubmed
pubmed-article:6546301pubmed:volume53lld:pubmed
pubmed-article:6546301pubmed:ownerNLMlld:pubmed
pubmed-article:6546301pubmed:authorsCompleteYlld:pubmed
pubmed-article:6546301pubmed:pagination368-73lld:pubmed
pubmed-article:6546301pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:meshHeadingpubmed-meshheading:6546301-...lld:pubmed
pubmed-article:6546301pubmed:year1984lld:pubmed
pubmed-article:6546301pubmed:articleTitleBone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study.lld:pubmed
pubmed-article:6546301pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6546301pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:6546301pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6546301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6546301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6546301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6546301lld:pubmed